We don't have a circular firing squad here yet, but honest
We don't have a circular firing squad here yet, but honest differences of opinion are well-warranted. To me it seems that DD could have been conducted more deliberately. So many deals came at us so quickly, it was hard to keep up. It seemed to me that things happened so quickly, that it was hard for Generex to assimilate them organically. My preference would have been for a smaller, better targeted company, but MMPJoe has big aspirations. It it too early to develop long term views during this relatively short time period.
However, was there a reason(s) for moving so quickly?
Did Generex overpay for some of the deals?
Was there some timeline that had to be met that caused mgmt. to rush?
Did mgmt. have too much trust in people they thought they knew?
Are there just too many irons in the fire?
What's the deal with Altucell?
I will definitely be glad when all the goodies are handed out. Maybe I'm putting too much trust in NGIO, but I still see AE37 as the potential flagship of the company. However, I also see the diabetes franchise as a close second, if Generex can pull it together. Let's get all the dividends out so that mgmt. can focus on the rest of the business plan. Who knows? We may be pleasantly surprised.
Wouldn't it make sense to get some sense of how the various initiatives are prioritized? How does mgmt. feel regarding the entire company? Is there dead wood that needs to be discarded, or are they in love with all its elements.
Wouldn't it be a good idea to outline all the potential initiatives in the next CC and obtain as thorough an update as possible for each?
The most important steps haven't changed since the Ol' Gennie days:
NASDAQ uplisting
Non-toxic funding
Execution of the business plan (I would like to see this fine-tuned.)
If we could get better insight into these elements of the company, decision making would be more precise for shareholders, IMO.
All that being said, I still have full confidence that MMPJoe is working as diligently as possible to get this turned around. There is much that he knows that we don't. It's our job to pull it out of him during the CC's. That what he has asked and that's what we should do.
5
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Another Year, Another Win for Sae-A Trading When was the last time you heard of an apparel manufacturer making waves for the right reasons? Sae-A Trading, the outfit under the Global Sae-A Group banner, is strutting its sustainability stuff by getting named as a UNGC LEAD Company for the second straight year. You better believe that’s not just for show – they’ve got...
Continue Reading
Cracking Cancer's Code: Mondego's Bold Move Big news from Portugal today—a quiet town called Cantanhede is now the epicenter of a potential game-changer in cancer therapy. Mondego Bio, with its small-molecule innovator MB?388, is diving headfirst into a Phase 1 clinical study. If you're scratching your head about the significance, let me spell it out: this is an attempt...
Continue Reading
California Schools Face Scrutiny Over Abuse Verdict Some days, the gavel falls, and its echo shakes up more than just a courtroom. That’s exactly what we’re seeing with this hefty $29 million verdict against ABC Unified School District. It’s not just a payout; it’s a bombshell that could change the landscape for how schools handle allegations of abuse. $29 Million...
Continue Reading
Crunching the Numbers on Utility Returns There's a buzz in the utility sector, and it's not just the hum of power lines—it’s all about return on equity (ROE). Concentric Energy Advisors just dropped some insights that could have us rethinking how these returns play into customer bills and utilities' financing capabilities. What's the Deal with ROE? Think of ROE like a...
Continue Reading
Slide Stainers Market Growth: A Closer Look In a world where precision and speed define medical success, the Slide Stainers Market is the silent hero no one talks about at cocktail parties. But make no mistake, its forecasted growth to $7.39 billion by 2031 shouts volumes in boardrooms and labs alike. With a modest start at $5.15 billion in 2026, this market is expected...
Continue Reading
Pope Leo XIV Embarks on Landmark Latin America Tour While Wall Street rumbles its daily tune, I've got my eyes on a different spectacle: Pope Leo XIV making rounds in South America from November 6 to 17. This isn't your typical news peg. This stretches beyond financial chatter into a spectacle of faith and cultural resonance. No price charts to weave here, just the...
Continue Reading
Big Wins on the Legal Stage When it comes down to the concrete jungle of construction law, Gerstle Snelson, LLP isn't just laying bricks; they're building skyscrapers. This Texas-based firm has secured three Regional Tier 1 rankings in the 2027 Best Law Firms® list. That's enough to make any law outfit puff out its chest a bit. What's in the Rankings? These rankings...
Continue Reading
Sasken's Bold Step Into Automotive Future Ah, nothing quite like the automotive industry trying to catch up with the tech world. That's where Sasken Technologies Ltd. stands, hand in hand with a major European automaker, rolling out the next phase of telematics control units (TCUs). This endeavor is a multi-year gig, not your fly-by-night partnership, mind you. It's all...
Continue Reading
A Dynamic Shift in Thrift Shopping All eyes might be on Thryfter this November as they drop some serious retail knowledge at the Goodwill CONNECT Conference in Houston. We’re talking about a tech shake-up for Goodwill’s model, thanks to Thryfter's livestream shopping craze that’s poised to weld traditional thrifting with digital reach. The Power of Virtual Thrift...
Continue Reading
This Isn't Your Grandma's Cash Back Here we go, folks! RetailMeNot is rolling out the red carpet for budget-conscious gift givers with its National Cash Back Day. From November 5–7, over 3,500 retailers, including big shots like Walmart and Ulta, are letting you scoop up to 30% in cold, hard cash back. If you ever needed a reason to start your holiday shopping early,...
Continue Reading
Top 5 Most Recently Viewed Articles
Cingulate Submits New Drug Application for CTx-1301 Cingulate Inc. (NASDAQ: CING), a pioneering biopharmaceutical company focused on addressing critical health issues, has taken a significant step forward by submitting its New Drug Application (NDA) for CTx-1301 to the U.S. Food and Drug Administration (FDA). This submission marks a crucial milestone for the company as it...
Continue Reading
AI's Pivotal Role in Biological Research Over at the Stowers Institute for Medical Research, things are heating up as Charles McAnany, Ph.D., steps into the role of AI Fellow. This ain't just another line on his CV; it's a ticket to the realms of enormous genetic data with AI as his guiding star. Artificial intelligence isn't new in the lab coats world, but the Institute...
Continue Reading
Exciting Developments in Crypto: The ExoraPad $EXP Token Launch The much-anticipated presale of the $EXP token, conducted by ExoraPad, is set to create significant waves in the crypto community. This event, scheduled for an upcoming date, is generating buzz among XRP enthusiasts. The presale aims to offer investors a unique opportunity to diversify their portfolios and...
Continue Reading
Hindenburg Research to Disband Following Recent Projects Hindenburg Research has made headlines for its thorough financial analysis and investigative efforts aimed at uncovering corporate misconduct. According to Nate Anderson, the founder of the firm, Hindenburg Research is set to dissolve its operations. This news was shared recently, clarifying that the decision comes...
Continue Reading
Significant Financial and Operational Updates from BiomX BiomX Inc. (NYSE American: PHGE) is making waves in the biotechnology sector with promising advancements in phage therapies aimed at tackling chronic infections. Recently, the company reported its financial results for the first quarter ending March 31, 2025, alongside pivotal updates regarding its clinical trials...
Continue Reading